|Home | About | Journals | Submit | Contact Us | Français|
There is a rise in the concurrent use of methylphenidate (MPH) and fluoxetine (FLX) in pediatric populations. However, the long-term neurobiological consequences of combined MPH and FLX treatment (MPH+FLX) during juvenile periods are unknown. We administered saline (VEH), MPH, FLX, or MPH+FLX to juvenile Sprague-Dawley male rats from postnatal day 20–35, and assessed their reactivity to reward- and mood-related stimuli 24-h or 2-months after drug exposure. We also assessed mRNA and protein levels within the ventral tegmental area (VTA) to determine the effect of MPH, FLX, or MPH+FLX on the extracellular signal-regulated protein kinase-1/2 (ERK) pathway – a signaling cascade implicated in motivation and mood regulation. MPH+FLX enhanced sensitivity to drug (i.e., cocaine) and sucrose rewards, as well as anxiety- (i.e., elevated plus-maze) and stress- (i.e., forced swimming) eliciting situations when compared to VEH-treated rats. MPH+FLX exposure also increased mRNA of ERK2 and its downstream targets cAMP response element-binding protein (CREB), brain-derived neurotrophic factor (BDNF), cFos, early growth response protein-1 (zif268), and mammalian target of rapamycin (mTOR), and also increased protein phosphorylation of ERK2, CREB, and mTOR 2-months after drug exposure when compared to VEH-treated rats. Using herpes simplex virus-mediated gene transfer to block ERK2 activity within the VTA, we rescued the MPH+FLX-induced behavioral deficits seen in the forced swimming task 2-months after drug treatment. These results indicate that concurrent MPH+FLX exposure during preadolescence increases sensitivity to reward-related stimuli while simultaneously enhancing susceptibility to stressful situations, at least in part, due to long-lasting disruptions in ERK signaling within the VTA.
Attention deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) often co-occur with up to 40% prevalence in pediatric populations (Waxmonsky, 2003; Spencer, 2006). The stimulant methylphenidate (MPH; Ritalin®), an effective agent for the management of ADHD (Castle et al., 2007), and the antidepressant fluoxetine (FLX; Prozac®), the only drug approved for treatment of pediatric MDD (Safer, 2006), are therapeutic agents often combined as a treatment strategy for co-morbid ADHD and MDD during early life (Rushton and Whitmire, 2001; Safer et al., 2003). Nevertheless, concerns regarding the safety and adverse effects associated with concomitant drug use in youths have emerged (Zito et al., 2008).
Despite prevalent MPH and FLX use, the neurobiological consequences of their combined use during juvenile periods are unknown (Bhatara et al., 2004; Spencer, 2006). This is particularly striking because together these drugs may have pharmacodynamic properties similar to cocaine. MPH and cocaine act through inhibition of dopamine transporters (Volkow et al., 2002), and the mechanistic differences between these drugs may be partly due to inhibition of serotonin transporters by cocaine, since MPH has a much lower affinity for the serotonin transporter (Han and Gu, 2006; Yano and Steiner, 2007). Thus, the concurrent use of MPH with the serotonin transporter blocker, FLX, may induce emergent effects similar to those of cocaine by simultaneously inhibiting the reuptake of both serotonin and dopamine. Accordingly, an acute dose of MPH+FLX robustly induces immediate early gene transcription and behavioral reactivity in adult rats, as cocaine does (Steiner et al., 2010).
The long-term consequences of juvenile exposure to MPH or FLX have only recently begun to be elucidated. MPH exposure in juvenile rats increases sensitivity to stress- and anxiety-eliciting situations while decreasing sensitivity to both natural and drug rewards in adulthood (Andersen et al., 2002; Bolaños et al., 2003a). Conversely, FLX treatment during adolescence increases sensitivity to anxiety-eliciting circumstances and to natural rewards, but decreases sensitivity to stress in adulthood (Karpova et al., 2009; Iñiguez et al., 2010a). The mechanisms underlying these long-lasting effects are unknown. However, signaling molecules linked to neurotrophic factors are increasingly implicated in the neural adaptations accompanying stress, psychostimulant, and antidepressant drug exposure (Bolaños and Nestler, 2004; Duman, 2004). Specifically, brain derived neurotrophic factor’s (BDNF) downstream target extracellular signal-regulated protein kinase-1/2 (ERK) and its targets cAMP response element-binding protein (CREB), mammalian target of rapamycin (mTOR), and the immediate early gene zif268 have been implicated in these cellular processes (Mutschler et al., 2000; Carlezon et al., 2005; Covington et al., 2005; Fumagalli et al., 2005; Lu et al., 2006; Iñiguez et al., 2010b; Subramaniam and Unsicker, 2010). Therefore, the major goal of this investigation was to assess the effect of juvenile MPH+FLX treatment on functional responsiveness to rewards, mood-related stimuli, and the expression of ERK-related molecules within the ventral tegmental area (VTA), a neural substrate implicated in the regulation of mood (Bolaños et al., 2003b; Eisch et al., 2003; Nestler and Carlezon, 2006; Iñiguez et al., 2010c).
Litters containing Sprague-Dawley male rat pups with their dams [Postnatal day (PD) 14 on arrival] (Charles River Laboratories) were used in this study. Rats were housed in clear polypropylene boxes containing wood shavings in an animal colony maintained at 23–25°C on a 12 h light-dark cycle in which lights were on between 7:00 and 19:00 h. Food and water were provided ad libitum. All procedures were in strict accordance with the guidelines for the Care and Use of Laboratory Animals (Council, 2003), and approved by the Florida State University Animal Care and Use Committee.
Methylphenidate hydrochloride (MPH), fluoxetine hydrochloride (FLX), and cocaine hydrochloride were obtained from Sigma (St. Louis, Missouri). Each drug was dissolved in 0.9% sterile saline (VEH) and administered in a volume of 1 mL/kg for MPH and cocaine, and 2 mL/kg for FLX and MPH+FLX. Intraperitoneal (i.p.) injections of MPH (2.0 mg/kg), FLX (2.5 mg/kg), MPH+FLX (2.0 and 2.5 mg/kg, respectively) or VEH were given to pups starting at PD20 twice daily (4 h apart) for 15 days (PD20–34). The dose of each drug was selected based on previous reports which have validated these dosing regimens to expected behavioral outcomes and approximate clinically-relevant dosing in humans (Wargin et al., 1983; Andersen et al., 2002; Bolaños et al., 2003a; Carlezon et al., 2003; Brenhouse et al., 2009; Steiner et al., 2010). From PD20 to PD23, VEH-, MPH-, and MPH+FLX-treated rats were kept together in the same cage with their dams. At PD24 (weaning), rats were separated by treatment condition into groups of four per cage. At PD45, rats assigned to the long-term testing condition were further separated into groups of two per cage and were left undisturbed until adulthood (PD94). Rats assigned to the short-term behavioral testing condition were tested on PD35, while those assigned to the long-term behavioral testing condition were tested in adulthood (PD94; see Figure 1). The period between PD20–34 was chosen because it approximates preadolescence (i.e., age 4–12 years) in humans (Spear, 2000; Andersen and Navalta, 2004). All behaviors, except for the place conditioning and sucrose preference tasks, were recorded with a video camera located on the ceiling of separate testing rooms. Rats were exposed to no more than two behavioral tasks. For specific testing sequence, see Table 1. Behavioral observations and analyses were performed by observers blind to the treatment conditions of each subject.
Place conditioning for cocaine was performed in a three-compartment apparatus as described previously (Andersen et al., 2002; Bolaños et al., 2008; Iñiguez et al., 2008). Compartments differed in floor texture, wall coloring, and lighting. On the preconditioning day (day 0), rats were allowed to explore the entire apparatus for 30 min to obtain baseline preference to any of the three compartments (side compartments: 35 × 27 × 25 cm; middle compartment: 10 × 27 × 25 cm, L × W × H). Only rats showing no preference (before cocaine exposure) to either side compartment were used; this accounted for more than 90% of all of the rats tested. Conditioning trials occurred over two consecutive days. During conditioning, rats received saline (1 mL/kg, i.p.) and were confined to one of the side compartments of the apparatus for 30 min. After three hours, rats received cocaine (0, 5, or 10 mg/kg, i.p.) and were confined to the opposite side compartment (drug-paired compartment) for 30 min. On the test day (day 3), rats received saline and were allowed to explore the entire apparatus for 20 min and time spent in the drug-paired compartment was assessed (drug side – saline side).
The sucrose preference test consisted of a two-bottle choice procedure in which rats were given the choice between consuming water and a sucrose solution. This paradigm has been used extensively to assess the effects of stress-induced anhedonia (Willner et al., 1987). Rats were habituated to drink water from two bottles for 5-days. At the start of the experiment, they were exposed to ascending concentrations of sucrose (0, 0.125, 0.25, 0.5, and 1%) for 2 days per sucrose concentration (Wallace et al., 2008). Water and sucrose consumption was measured at 8:00 and 17:00 h each testing day. The position of the sucrose bottle (left or right) was counterbalanced between groups and changed daily. Preference for sucrose over water [sucrose/(sucrose+water)] was used as a measure for rats’ sensitivity to reward.
VEH-, MPH-, FLX, and MPH+FLX-pretreated rats were tested on the elevated plus-maze, a behavioral task assessing anxiety-like behavior (Montgomery and Monkman, 1955). The maze consisted of two perpendicular, intersecting runways (12 cm wide × 100 cm long) made from gray plastic. One runway had tall walls (40 cm high), termed “closed arms,” while the other had no walls, termed “open arms.” The arms were connected together by a central area, and the maze was elevated one m from the floor. Testing was conducted between 09:00 and 13:00 h under controlled light conditions (~90 lux) as described previously (Bolaños et al., 2003a; Iñiguez et al., 2009). At the start of the test, rats were positioned in the central area, facing one of the open arms and allowed to explore freely for five min, and the percent time that the rat’s center-point (as determined by Noldus Ethovision XT) spent in the open versus closed arms was measured [100 × (Total time spent in open arms/Total time spent in closed arms)].
The forced swim test is a two day procedure in which rats are forced to swim under inescapable conditions (Porsolt et al., 1977). On day 1, rats are forced to swim for 15-min. Initially, they engage in escape-like behaviors but eventually adopt a posture of immobility in which they make only the movements necessary to maintain their head above water. When retested 24-h later, rats become immobile very quickly; however, antidepressant treatment between the forced swim exposures can significantly increase their escape-like behaviors, an effect that has been correlated with antidepressant activity in humans (Cryan et al., 2002). At the start of the experiment, rats were placed in plastic cylinders (75 × 30 cm) filled to 54 cm depth with 25°C water, as described previously (Iñiguez et al., 2009). Afterward, rats were removed from the water, dried with towels, and placed in a warmed enclosure for 30 min. All cylinders were emptied and rinsed between rats. On day 2 (24 h later), rats were retested for five min under identical conditions. Here, the latency to become immobile, total immobility, swimming-, climbing-, and immobility- counts were measured. Behavioral counts were taken at five sec intervals during the five min retest. Latency to immobility was defined as the time at which the rat first initiated a stationary posture that did not reflect attempts to escape from the water (Lucki, 1997). To qualify as immobility, this posture had to be clearly visible and maintained for ≥ 2.0 sec (Detke and Lucki, 1996; Carlezon et al., 2003).
Spontaneous locomotor activity was indexed as distance traveled (cm) in an automated open-field (63 × 63 cm) that consisted of a square box that rats can explore freely (Wiley et al., 2009; Iñiguez et al., 2010a). This behavioral task was performed 24-h after the forced swim test on day 1, in order to assess whether the effects observed in the forced swim test (day 2) could be confounded by changes in general locomotor activity after drug pretreatment or viral surgery.
Rats were sacrificed either 24-h or 2-months after the last injection of VEH, MPH, FLX, or MPH+FLX. Punches were taken from VTA (1.25 mm) and stored at −80°C until use. RNA was isolated using RNEasy Micro kits (Qaigen) and cDNA was created from these samples using iScript cDNA synthesis kit (Bio-Rad; Hercules, California). qPCRs were performed in triplicate using 96 well PCR plates and RealMasterMix (Eppendorf) with an Eppendorf MasterCycler Realplex2 according to manufacturer’s instructions. Threshold cycle [C(t)] values were measured using the supplied software and analyzed with the ΔΔC(t) method as described previously (LaPlant et al., 2010; Vialou et al., 2010). Primer sequences for ERK2, CREB, BDNF, cFos, Zif268, mTOR, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are listed in Table 2.
Tissue punches of VTA (1.25 mm diameter) from rats were sonicated in a standard lysis buffer and then centrifuged at 14,000 rpm for 15 min. Samples (20 µg; estimated through Bradford assay) were treated with β-mercaptoethanol and subsequently electrophoresed on precast 4%–20% gradient gels (Biorad, Hercules, California), as previously described (Iñiguez et al., 2011). Proteins were transferred to a polyvinylidene fluoride membrane, washed in 1X Tris-buffered saline with 0.1% Tween-20 (TBST), and blocked in milk dissolved in TBST (5% weight/volume) for one h at 25°C. Blots were probed (overnight at 4°C) with antibodies against the phosphorylated forms of ERK2, CREB, and mTOR, stripped with Restore (Pierce Biotechnology, Rockford, Illinois) and re-probed with antibodies against total CREB, ERK2, mTOR, and GAPDH. All antibodies were from Cell Signaling (Beverly, Massachusetts) and were used according to manufacturer’s instructions in 5% milk dissolved in TBST. After further washes, membranes were incubated with peroxidase-labeled goat anti-rabbit IgG or horse anti-mouse IgG (1:40,000; Vector Labs, Burlingame, California). Bands were visualized with SuperSignal West Dura substrate (Pierce Biotechnology, Rockford, Illinois), quantified using ImageJ (NIH) and normalized to GAPDH.
Based on the results from the behavioral experiments described above, separate groups of juvenile male rats were treated with MPH+FLX from PD20–34. Two months after the end of drug treatment (PD94), they were microinjected with herpes simplex virus (HSV) vectors encoding green fluorescent protein (GFP) or a dominant negative mutant of ERK2-GFP (dnERK2) within the VTA to assess whether blockade of ERK2 itself would rescue the MPH+FLX-induced behavioral deficits as measured in the forced swim test. The construction of the HSV vectors has been described previously (Robinson et al., 1996; Neve et al., 1997), and the HSV-GFP and the HSV-dnERK2 vectors have been validated in vivo and in vitro (Krishnan et al., 2007; Russo et al., 2007; Iñiguez et al., 2010c). The average titer of the recombinant virus stocks was 4.0 × 107 infectious units/ml. Titers did not differ by >10% among preparations. The behavioral experiment was commenced on day three after viral surgery (PD97), a time at which maximal transgene expression caused by these vectors is observed (Carlezon et al., 1998; Barrot et al., 2002). As previously reported, expression of the HSV-encoded transgenes was limited to an area of ~1 mm3 around the injection site, and viral expression was not apparent in either afferent or efferent regions of the injected area (Bolaños et al., 2003b; Iñiguez et al., 2008; Krishnan et al., 2008).
For stereotaxic delivery of the viruses, rats were anesthetized with a ketamine/xylazine cocktail (80/10 mg/kg; intramuscular) and given atropine (0.25 mg/kg) subcutaneously to minimize bronchial secretions; afterward, rats were given bilateral microinjections (1.0 µl per side over 10 min of either HSV-GFP or -dnERK2) into the rostral region of the VTA [anteroposterior, −4.9 mm, lateral, +2.2 mm, dorsoventral, −7.6 mm below dura (Paxinos and Watson, 1997)] using a 32 gauge Hamilton syringe angled at 10° from the midline, to avoid piercing the sinus system. The local anesthetic bupivacaine was applied directly along the wound edges to minimize any potential postoperative discomfort. The VTA injection sites were confirmed in all rats by standard histology methods (described below).
At the end of the forced swim test, rats were given an overdose of pentobarbital and perfused transcardially with 0.9% saline, followed by cold 4% paraformaldehyde. The brains were removed, postfixed overnight in 4% paraformaldehyde and stored in 20% glycerol. Coronal sections (45 µm) through the midbrain were taken on a microtome and stored in 0.1 M sodium phosphate buffer with 0.05% azide. Sections were processed to examine the ability of HSV construct to drive expression of GFP and Tyrosine Hydroxylase (TH) within the VTA as previously described (Russo et al., 2007; Iñiguez et al., 2010c). Midbrain free-floating coronal sections were processed for immunohistochemistry using the following antibodies: rabbit anti-GFP (1:1000; Abcam, Cambridge, Massachusetts), and anti-TH (mouse; 1:5000, Chemicon, Temecula, California), a marker of VTA dopamine neurons. Adjacent sections were blocked in 3% normal donkey serum (NDS) and incubated overnight in one of the primary antibodies mentioned above, along with 0.3% Triton X-100 (Fisher Scientific, Pittsburgh, Pennsylvania) and 1% NDS. Sections were incubated with anti - rabbit or -mouse secondary antibody (Jackson ImmunoResearch, West Grove, Pennsylvania) for two h at room temperature. Stained sections were then slide mounted (Fisher Scientific), dehydrated in ethanol and citrosolv, and coverslipped with clear DPX adhesive (Sigma, St. Louis, Missouri). Slides were then visualized and photographed using a fluorescence microscope and a digital camera. Data obtained from rats with placements outside the intended brain regions (<10% of all experimental animals) were not included in the analyses.
Data analysis was assessed using mixed-design (between and within variables) analysis of variance (ANOVA) followed by Least Significant Difference (LSD) post hoc tests. When appropriate, Student’s t tests were used to determine statistical significance of preplanned comparisons. Data are expressed as the mean ± SEM. Statistical significance was defined as p< 0.05.
Sensitivity to cocaine was assessed 24-h (short-term; N= 78) or 2-months (long-term; N= 77) following juvenile exposure to VEH, MPH, FLX, or MPH+FLX (Figure 2). No effects were detected in rats conditioned with saline 24-h after chronic drug treatment (Figure 2A). Time spent in the cocaine-paired compartment varied as a function of drug pre-treatment (F(3,66)= 11, p< 0.01), cocaine dose (F(2,66)= 44.5, p< 0.01), and the interaction between the two independent variables (F(6,66)= 7.4, p< 0.01). VEH-pretreated rats spent significantly more time in the 10 mg/kg cocaine-paired compartments when compared to the lower doses (0 and 5 mg/kg) of cocaine (p< 0.05; n= 6–7 per group). Conversely, MPH-pretreated rats did not develop preference for any of the cocaine-paired compartments when compared to the VEH-pretreated controls (p> 0.05; n= 5–7 per group). FLX-pretreated rats spent significantly more time in the 10 mg/kg cocaine-paired compartments (p< 0.05; n= 5–8 per group), whereas rats in the MPH+FLX pretreatment condition showed increased place preference at both the 5 and 10 mg/kg cocaine doses when compared to the VEH-pretreated controls (p< 0.05; n= 5–9 per group).
We also tested for cocaine-induced place conditioning in the rats exposed to VEH, MPH, FLX, or MPH+FLX as juveniles and assigned to the long-term condition (i.e., 2-months after the last drug injection; Figure 2B). No effects were detected in rats conditioned with saline regardless of juvenile drug pre-treatment. Time spent in the cocaine-paired compartments varied as a function of juvenile drug treatment (F(3,65)= 17.1, p< 0.01), cocaine dose (F(2,65)= 5.8, p< 0.01), and the interaction between the two variables (F(6,65)= 8.2, p< 0.01). As expected, VEH-pretreated rats conditioned to the cocaine-paired compartments in a dose-dependent manner (p< 0.05; n= 6–7 per group), whereas the MPH-pretreated rats avoided the cocaine-paired compartments regardless of dose when compared to the VEH-pretreated controls (p< 0.05; n= 5–8 per group). The FLX- and MPH+FLX-pretreated rats (n= 5–8 per group, respectively) readily conditioned to the cocaine-paired compartments in a dose-dependent manner when compared to the VEH-pretreated controls (p< 0.05, respectively). Interestingly, further analysis indicated that the magnitude of place conditioning developed by the MPH+FLX-pretreated rats was significantly higher when compared to the FLX-treated group at both cocaine doses (p< 0.05, respectively), indicating that combined MPH+FLX pretreatment potentiated the effects of cocaine in this behavioral task.
We then assessed sensitivity to a natural reward, namely sucrose, 2-months after juvenile exposure to VEH, MPH, FLX, or MPH+FLX using the sucrose preference test on a separate group of rats (Figure 3; N= 40; 9–11/group). Juvenile drug pre-exposure did not influence total fluid intake (water+sucose; Figure 3B) in adulthood (p> 0.05). However, a repeated measures ANOVA indicated that preference for sucrose varied as a function of juvenile drug treatment (F(3,144)= 15.7, p< 0.01), sucrose concentration (F(4,144)= 173.8, p< 0.01), and the interaction between the two independent variables (F(12,144)= 3.5, p< 0.05). MPH pretreatment decreased preference for sucrose at the 0.125, 0.25, and 0.5% concentrations (p< 0.05, respectively), whereas FLX pretreatment increased sucrose preference only at the 0.5% concentration when compared to the VEH-pretreated controls (p< 0.05). MPH+FLX pretreatment increased preference for sucrose at both the 0.5% and 1.0% concentrations when compared to the VEH-pretreated controls (p< 0.05, respectively).
The short- and long-term effects of juvenile drug exposure (VEH, MPH, FLX, or MPH+FLX) on behavioral response to anxiogenic stimuli are shown in Figure 4. The percent time spent in the open arms of the elevated plus-maze varied as a function of juvenile drug pretreatment 24-h after the last injection (F(3,26)= 3.0, p< 0.05; Fig. 4, left panel). MPH pretreatment decreased time spent in the open arms, whereas FLX and MPH+FLX pretreatment did not influence behavioral responding on this task when compared to the VEH-pretreated controls (p> 0.05; N= 30; 7–8 per group group).
We then assessed the long-term effects of juvenile VEH, MPH, FLX, or MPH+FLX exposure in separate groups of rats (Fig. 4, right panel; N= 40; 8–12/group). The percent time spent in the open arms of the elevated plus-maze was affected by juvenile drug pretreatment (F(3,36)= 12.9, p< 0.001). MPH-, FLX-, and MPH+FLX-pretreated rats spent significantly less time in the open arms when compared to the VEH-treated controls (p<0.05, respectively).
We used the forced swim test to assess rats’ responsiveness to behavioral despair 24-h after juvenile VEH, MPH, FLX, or MPH+FLX treatment (N= 30) or when they reached adulthood (N= 30; Fig. 5A–E). Juvenile drug treatment influenced rats’ latency to become immobile (F(3,26)= 4.6, p< 0.05), total immobility (F(3,26) = 4.0, p< 0.05), and counts of immobility (F(3,26)= 4.7, p< 0.01), swimming (F(3,26)= 8.3, p< 0.05), and climbing (F(3,26)= 14.8, p< 0.05) when tested 24-h after the last injection (Fig. 5A–D, left panel; n= 7–8 per group). Specifically, MPH pretreatment had no effect on latency to immobility, total immobility, or swimming-counts (p> 0.05), but decreased immobility- and increased climbing-counts when compared to the VEH-pretreated controls (p< 0.05, respectively). Conversely, FLX pretreatment increased latency to immobility and decreased total immobility, while increasing swimming- and climbing- and decreasing immobility-counts when compared to the VEH-pretreated controls (p< 0.05, respectively). Combined MPH+FLX pretreatment did not affect latency to immobility or total immobility (p> 0.05), but increased swimming- and climbing-, while decreasing immobility-counts when compared to the VEH-pretreated controls (p< 0.05, respectively).
Separate groups were treated with VEH, MPH, FLX, or MPH+FLX as juveniles and tested in adulthood (Fig. 5A–E, right panels). Separate one-way ANOVAs revealed significant differences in latency to become immobile (F(3,26)= 8.4, p< 0.01), total immobility (F(3,26)= 7.5, p< 0.01), and counts of immobility (F(3,26)= 16.2, p< 0.01), swimming (F(3,26)= 15.1, p< 0.01), and climbing (F(3,26)= 5.0, p< 0.05) as a function of juvenile drug pretreatment (n= 6–8 per group). MPH pretreatment decreased latency to immobility, increased total immobility, decreased swimming-, and increased immobility-counts, without affecting climbing-counts (p> 0.05), when compared to the VEH-pretreated controls (p< 0.05, respectively). FLX pretreatment decreased total immobility (p< 0.05) without affecting latency to immobility (p> 0.05), but increased swimming- and climbing- while decreasing immobility-counts when compared to the VEH-pretreated controls (p< 0.05, respectively). MPH+FLX pretreatment significantly decreased latency to immobility (interpreted as increased susceptibility to stress; p< 0.05), had no effect on total immobility (p> 0.05), but decreased swimming- and increased immobility-, but not climbing-counts (p> 0.05), when compared to the VEH-pretreated controls (p< 0.05, respectively).
ERK-related gene expression within the VTA was measured 24-h after juvenile exposure to VEH, MPH, FLX, or MPH+FLX using qPCR (Fig. 6; N= 32; 8 per group). ERK2 (F(3,28)= 28.14, p< 0.01; Fig. 6A), CREB (F(3,28)= 31.7, p< 0.01; Fig. 6B), Zif268 (F(3,28)= 14.5, p< 0.01; Fig. 6E), and mTOR (F(3,28)= 5.0, p< 0.05 Fig. 6F) mRNA varied as a function of juvenile drug exposure 24-h after treatment, whereas BDNF (p> 0.05; Fig. 6C) and cFos (p> 0.05; Fig. 6D) were not affected at this time point. MPH pretreatment had no effect on BDNF or cFos (p> 0.05), but decreased ERK2 and CREB (p< 0.05, respectively) while increasing Zif268 and mTOR mRNA (p< 0.05, respectively) when compared to the VEH-pretreated controls. FLX pretreatment decreased ERK2 and CREB (p< 0.05, respectively) and increased mTOR mRNA (p< 0.05), while having no effect on BDNF, cFos, or Zif268 mRNA (p> 0.05) when compared to the VEH-pretreated controls. MPH+FLX pretreatment increased ERK2, CREB, and Zif268 mRNA (p< 0.05, respectively), but had no effect on BDNF, cFos, or mTOR mRNA when compared to the VEH-pretreated controls (p> 0.05).
Figure 7 shows the effects of VEH, MPH, FLX, and MPH+FLX on ERK-related gene expression 2-months after juvenile drug exposure (N= 32; 8/group). Separate one-way ANOVAs indicated that ERK2 (F(3,28)= 5.6, p< 0.01; Fig. 7A), CREB (F(3,28)= 3.9, p< 0.05; Fig. 7B), BDNF (F(3,28)= 3.4, p< 0.05; Fig. 7C), cFos (F(3,28)= 6.1, p< 0.01; Fig. 7D), Zif268 (F(3,28)= 3.2, p< 0.05; Fig. 7E), and mTOR (F(3,28)= 4.4, p< 0.05; Fig. 7F) mRNA varied as a function of juvenile drug pretreatment. More specifically, MPH had no effect on ERK2, CREB, or BDNF mRNA when compared to the VEH-pretreated controls (p> 0.05). Nevertheless, MPH pretreatment increased cFos and Zif268, while decreasing mTOR mRNA when compared to the VEH-pretreated controls (p< 0.05, respectively). FLX pretreatment decreased BDNF (p< 0.05), without affecting ERK2, CREB, cFos, Zif268, or mTOR mRNA when compared to the VEH-pretreated controls (p> 0.05). MPH+FLX pretreatment increased ERK2, CREB, BDNF, cFos, Zif268, and mTOR mRNA when compared to the VEH-pretreated controls (p< 0.05, respectively).
We further assessed the activity of ERK signaling 2-months after VEH or MPH+FLX juvenile exposure as inferred from the phosphorylation of ERK2 protein and two downstream targets, CREB and mTOR (Fig. 8; N= 16; 8 per group). MPH+FLX exposure increased levels of phosphorylated ERK2 (t14= 2.3, p< 0.05; Fig. 8A), CREB (t14= 4.6, p< 0.01; Fig. 8B), and mTOR (t14= 2.0, p< 0.05; Fig. 8C) protein within the VTA when compared to the VEH-pretreated controls (all normalized to GAPDH and presented as % of phosphorylated protein). No changes in total ERK2, total CREB, total mTOR, or GAPDH protein levels were detected when compared to the VEH-pretreated controls (p> 0.05).
Based on the ability of juvenile MPH+FLX treatment to increase ERK2 signaling within the VTA in adulthood, and since increasing ERK activity increases susceptibility to stress (Iñiguez et al., 2010c), it was of interest to assess the functional consequences of decreasing ERK activity in this brain region on behavioral despair, namely the forced swim behavioral task. To this end, ERK2 signaling was reduced within the VTA of adult rats pretreated with MPH+FLX as juveniles by local injection of HSV-dnERK2 and responsivity to behavioral despair was assessed. We also tested five additional control groups as follows: VEH-pretreated rats + sham surgery, VEH-pretreated rats + HSV-GFP, VEH-pretreated rats + HSV-dnERK2, MPH+FLX-pretreated rats + sham surgery, and MPH+FLX-pretreated rats + HSV-GFP.
Figure 9A shows the region of the VTA to which sham or microinjections of HSV vectors (HSV-GFP or -dnERK2) were targeted. As reported previously, viral-encoded transgene expression was maximal between days three and four after injection (data not shown), significantly declining thereafter, and undetectable one week after the microinjection (Carlezon et al., 1997; Barrot et al., 2002; Olson et al., 2005). Confocal microscopy (Fig. 9B–D) revealed that the percentage of TH-positive neurons overexpressing GFP in the VTA (~55%) was similar to previous findings (Olson et al., 2005; Russo et al., 2007) with no detectable expression of the viral-encoded transgenes in glial cells (data not shown).
The effects of VEH+sham, VEH+HSV-GFP, VEH+HSV-dnERK2, MPH+FLX-sham, MPH+FLX-HSV-GFP, and MPH+FLX-HSV-dnERK2 surgeries on day 2 of forced swimming are shown in figure 9 (N= 47, 6–10 per group). The amount of time rats engaged in escape-directed behaviors in the forced swim test varied as a function of viral post-treatment. Specifically, latency to immobility varied as a function of virus post-treatment (F(5,42)= 8.6, p< 0.001; Fig. 9E). VEH-pretreated rats receiving microinjections of HSV-dnERK2, but not HSV-GFP, demonstrated significantly higher latencies to immobility (interpreted as increased resilience to stress) when compared to the VEH+sham controls (p< 0.05). MPH+FLX-pretreated rats receiving sham surgery or HSV-GFP post-treatment had lower latencies to become immobile when compared to the VEH+sham controls (p> 0.05). However, the latency to immobility demonstrated by the MPH+FLX-pretreated rats microinjected with HSV-dnERK2 was increased when compared with the MPH+FLX-pretreated rats receiving sham surgery or HSV-GFP within the VTA (p< 0.05, respectively). Further analyses indicated that total immobility (F(5,42)= 8.5, p< 0.001; Fig. 9F) and immobility-counts (F(5,42)= 4.7, p< 0.002; Fig. 9G, left panel) also varied as a function of virus post-treatment. However, behavioral counts of swimming and climbing did not reach statistical significance (Fig. 9G, middle and right panels, respectively; p> 0.05). VEH-pretreated rats receiving either microinjections of HSV-GFP or HSV-dnERK2-GFP did not differ from the VEH+sham controls (p> 0.05). MPH+FLX-pretreated rats receiving sham surgery or HSV-GFP had significantly higher levels of total immobility and increased immobility-counts when compared to the VEH+sham controls (p< 0.05, respectively). Conversely, MPH+FLX-pretreated rats microinjected with HSV-dnERK2 did not differ from the VEH+sham controls in total immobility or immobility-counts when compared to the VEH+sham controls (p> 0.05), but demonstrated decreased total immobility and lower immobility-counts (p< 0.05, respectively) when compared to the MPH+FLX-pretreated rats receiving HSV-GFP within the VTA, indicating that viral-mediated blockade of ERK2 activity with HSV-dnERK2 reversed the effects of MPH+FLX pretreatment on measures of behavioral despair.
A separate group of VEH- and MPH+FLX-pretreated rats receiving VEH+sham, VEH+ HSV-GFP, VEH+HSV-dnERK2, MPH+FLX-sham, MPH+FLX-HSV-GFP, and MPH+FLX-HSV-dnERK2 into the VTA (n= 4–5 per group) were tested in the open field to assess general locomotor activity after sham surgery or viral-mediated gene transfer (Fig. 9H). No significant differences were apparent between the groups when locomotor activity was assessed 24-h after day 1 of forced swimming (p> 0.05).
This study assessed the neurobiological consequences of concomitant exposure to MPH and FLX, two drugs that are often combined for the management of comorbid ADHD and MDD in pediatric populations (Bhatara et al., 2004). We show that chronic juvenile administration of MPH, FLX, or MPH+FLX alters responsiveness to both rewarding and aversive situations, and disrupts VTA ERK2 expression/signaling. Blockade of VTA ERK2 activity rescued the MPH+FLX-induced behavioral deficits in forced swimming, like administration of antidepressants (Lucki, 1997; Iñiguez et al., 2010a).
Juvenile exposure to MPH, FLX, or MPH+FLX changed responsivity to appetitive stimuli. MPH pretreatment reduced, whereas FLX and MPH+FLX pretreatment increased sensitivity to cocaine place conditioning. Interestingly, MPH+FLX pretreatment induced conditioned place preference at a dose that had no effect in the VEH- or FLX-pretreated rats (5 mg/kg), suggesting that MPH+FLX enhances sensitivity to drug reward. The long-term effects were particularly striking: while MPH pretreatment induced a significant aversion to cocaine, the FLX- and MPH+FLX-pretreated rats readily preferred the cocaine-paired compartments. Similarly, MPH blunted, while FLX and MPH+FLX pretreatments increased sucrose preference in adulthood, likely by changing sensitivity to reward, since total liquid consumption did not differ. Interestingly, the effects of MPH+FLX were not intermediate, since MPH decreased preference for sucrose. This suggests that FLX is not simply reversing the MPH-induced deficits, but that FLX may interact with MPH to increase sensitivity to both drug and natural rewards. These findings support reports demonstrating that exposure to MPH or FLX during early life leads to long-lasting adaptations in brain reward pathways (Mague et al., 2005; Thanos et al., 2007; Iñiguez et al., 2010a) and suggest that concurrent exposure may enhance this effect (Steiner et al., 2010). Though we demonstrate that MPH+FLX pretreatment increased sensitivity to reward, this is not necessarily maladaptive and may not represent enhanced addiction potential (Tzschentke, 1998).
Our findings also indicate that juvenile MPH, FLX, and MPH+FLX treatment influences rats’ responsiveness to anxiety- and stress-inducing situations. Short-term, MPH pretreatment enhanced reactivity to the elevated plus-maze, whereas FLX or MPH+FLX did not. Conversely, MPH, FLX, and MPH+FLX pretreatments enhanced responsivity to anxiogenic stimuli long-term. This is not surprising, since juvenile exposure to MPH or FLX has been shown to induce an anxiogenic phenotype in adulthood (Bolaños et al., 2003a; Karpova et al., 2009; Iñiguez et al., 2010a). Forced swimming results showed that MPH and MPH+FLX did not influence behavioral despair, whereas FLX induced a stress-resistant phenotype 24-h after treatment (Iñiguez et al., 2010a). As adults, MPH- and MPH+FLX-pretreated rats showed enhanced susceptibility to swimming stress, whereas FLX-pretreated rats showed decreased vulnerability. Together, these data support evidence that juvenile exposure to MPH induces enduring vulnerability to stress (Lagace et al., 2006; Halladay et al., 2009; Wiley et al., 2009), while FLX exposure results in an anxiogenic and stress-resistant behavioral phenotype in adulthood (Karpova et al., 2009; Iñiguez et al., 2010a). We now extend these findings to combined juvenile MPH+FLX exposure. While the forced swim test is a valid and reliable animal model, results can be variable across its dependent measures (Reed et al., 2008; Iñiguez et al., 2009). Long-term, MPH+FLX pretreated rats did not show substantial change in total immobility, but did show a “depression-like” behavioral profile in latency to immobility, swimming, and immobility counts. Furthermore, a separate group of MPH+FLX-pretreated rats receiving sham or HSV-GFP surgeries showed increased total immobility (Fig. 9F).
The mechanism(s) underlying these behavioral effects are unknown. Given the pharmacodynamic properties of MPH and FLX and that dopamine and serotonin systems interact (Benloucif et al., 1993; De Deurwaerdere et al., 1996; Bolaños et al., 2002), it has been suggested that concurrent use of these drugs may induce cocaine-like effects (Yano and Steiner, 2007). In line with this hypothesis, acute MPH+FLX or cocaine treatment in adult rats have similar biochemical and behavioral effects (Borycz et al., 2008; Van Waes et al., 2010). Cocaine also induces anxiety- and depression-like behaviors in juvenile and adult rats (Blanchard and Blanchard, 1999; Perrine et al., 2008). However, juvenile cocaine exposure decreases sensitivity to cocaine in adulthood (Carlezon et al., 2003), an effect opposite to our finding following MPH+FLX pretreatment. This finding may discount the suggestion that MPH+FLX acts as a cocaine-mimetic, but supports a view that when combined, MPH+FLX induces complex effects distinct from MPH, FLX, or cocaine alone. Accordingly, MPH+FLX treatment did not enhance the effects of either drug across all behavioral measures. Specifically, MPH+FLX induced a behavioral profile similar to FLX 24-h after treatment. When tested in adulthood, MPH+FLX induced a behavioral phenotype distinctive from either MPH or FLX alone: MPH+FLX increased vulnerability to stress (like MPH-pretreated rats) and enhanced sensitivity to both cocaine and sucrose rewards (like FLX-pretreated rats). Therefore, it is unlikely that one drug is simply enhancing the effects of the other, and differences in dosing, age, length of drug exposure, metabolism, as well as the complex interaction between two complicated and poorly understood drug pathways must be considered (Bolaños et al., 1998; Carlezon and Konradi, 2004).
We also measured the expression of ERK-driven signaling molecules within the VTA after juvenile drug treatment, since MPH and FLX interact with the VTA and the nucleus accumbens (Yang et al., 2006; Sekine et al., 2007), neural substrates mediating responses to rewarding and aversive stimuli (Nestler and Carlezon, 2006; Wallace et al., 2009; LaPlant et al., 2010). We show that ERK2/CREB mRNA was decreased by MPH or FLX alone, but unexpectedly elevated by combined MPH+FLX 24-h after treatment; while increases in CREB and Zif268 mRNA in MPH+FLX pretreated rats accompanied increased ERK2 mRNA (Turgeon et al., 1997; McClung and Nestler, 2003). Surprisingly, ERK2 mRNA was upregulated 2-months after MPH+FLX exposure. This is particularly interesting because neither MPH nor FLX induced similar increases when administered alone, suggesting long-lasting differences between combined and individual pretreatments. Whether this effect is due to drug-induced ontogenetic changes is unknown, however, in adult rodents chronic exposure to psychostimulants increases ERK activity, resulting in CREB activation and the subsequent transcription of cFos and zif268 (Lu et al., 2006), while FLX exposure decreases ERK phosphorylation and reduces CREB activation (Fumagalli et al., 2005; Boer et al., 2010). Together, these results underscore the complexity of drug-induced effects in the immature brain, and detailed assessments of these phenomena are needed. Because increased gene expression does not necessarily result in increased protein levels and may not represent increased activity of these enzymes (Lee et al., 2003; Mehra et al., 2003), we assessed phosphorylation levels of key ERK-related proteins 2-months after juvenile MPH+FLX exposure. We found increased phosphorylation of ERK2, CREB, and mTOR proteins within the VTA, with no change in total levels of these proteins. Given reports implicating mTOR activity within the prefrontal cortex in the antidepressant effects observed after ketamine treatment (Li et al., 2010), MPH+FLX-induced mTOR activity may seem counterintuitive. However, manipulations of ERK-related molecules in different brain regions often result in varying behavioral effects (Berton et al., 2006; Krishnan et al., 2007). Thus, a pro-depressant behavioral phenotype and increased mTOR activity within the VTA after MPH+FLX exposure is not surprising, but does require further analysis.
We further demonstrate a role for ERK in the MPH+FLX-induced behavioral effects by decreasing ERK2 activity within the VTA of MPH+FLX-pretreated rats, using viral-mediated gene transfer. Decreased ERK2 activity rescued the pro-depressant MPH+FLX-induced phenotype by increasing escape-like behaviors in the forced swim test, effects similar to those elicited by antidepressant treatments (Cryan et al., 2002). This did not result from deficits in motor activity because viral treatment did not affect basal locomotion (Fig. 9H). These findings mirror reports that stress increases ERK2 signaling within the VTA (Iñiguez et al., 2010c), and that overexpressing ERK2 (Iñiguez et al., 2010c), or infusing BDNF (Eisch et al., 2003; Lu et al., 2004) in the VTA induces anxiety- and depression-like states while enhancing drug reward (Bolaños and Nestler, 2004; Iñiguez et al., 2010b). Additionally, increased VTA-ERK activity after MPH+FLX supports the notion that concurrent treatment with these drugs may be pharmacodynamically similar to treatment with cocaine (Yano and Steiner, 2007; Steiner et al., 2010) and suggests that combining MPH and FLX early in life may lead to life-long behavioral and biochemical abnormalities. Importantly, the present study did not assess reward-related behavior following viral manipulation of ERK2 signaling. Recently, we have shown that HSV-ERK2 modulates responsiveness to cocaine reward (Iñiguez et al., 2010b), but whether viral knockdown of ERK2 would reverse MPH+FLX-induced sensitivity to reward remains unknown.
In summary, our study shows that juvenile exposure to combined MPH+FLX increases sensitivity to reward, anxiety- and stress-eliciting situations later in life, and implicates dysregulated ERK signaling within the VTA as a potential mechanism(s) underlying these effects. It is imperative to note, however, that the MPH+FLX-induced effects described in this study were derived from “normal” animals, and similar MPH+FLX treatment in an animal model of ADHD/MDD comorbidity might yield different results. Furthermore, studies assessing potentially enduring side-effects of MPH+FLX in humans are lacking (Daviss, 2008), making interpretative parallels challenging. Our findings necessitate further study into the effects of early life drug exposure on functional outcomes in adulthood.
This work was supported by grants R21DA022351-01 and R011DA026854-01 from the National Institute on Drug Abuse (NIDA). BLW was supported by a Neuroscience Fellowship from Florida State University. SDI was supported by a McKnight Fellowship from the Florida Education Fund, a Neuroscience Fellowship from Florida State University, and a NRSA (F31DA027300) from NIDA. The authors are grateful to Dr. Eric J. Nestler for generously providing the viral vectors used in these studies, to Dr. Vaishnav Krishnan for insightful discussions on earlier versions of the manuscript, and to Raul J. Arispe for editorial assistance.